Actively Recruiting
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Led by Innovent Biologics Technology Limited (Shanghai R&D Center) · Updated on 2026-02-04
300
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).
CONDITIONS
Official Title
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and sign informed consent for all study procedures
- Male or female aged 18 years or older
- At least one measurable lesion per RECIST v1.1 within 28 days before first dose
- ECOG performance status of 0 or 1
- Life expectancy of at least 12 weeks at treatment start
- Good bone marrow and organ function confirmed during screening
- Non-reproductive potential or agreement to use effective contraception during study and for 6 months post-treatment
- Not suitable for curative surgery or definitive chemoradiotherapy
You will not qualify if you...
- Prior treatment with IL-12 cytokines or IL-12 inhibitors
- Participation in other interventional clinical studies or in follow-up of such studies
- Unresolved adverse reactions from prior anti-tumor therapies above Grade 1 (except certain exceptions)
- Severe adverse reactions from prior immune checkpoint inhibitor therapy compromising safety
- Known allergy or intolerance to IBI3026 or its ingredients
- Major surgery within 4 weeks before first dose or planned during study, excluding core biopsy
- Serious non-healing wounds, trauma, or ulcers
- Symptomatic central nervous system metastases; asymptomatic allowed if stable and meeting criteria
- Tumor invading critical nearby structures or risk of gastrointestinal/respiratory fistula formation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan Cancer Hospital
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
H
Haiyun Zuo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here